作者
Zaira Raquel Palacios-Baena, Belén Gutiérrez-Gutiérrez, Esther Calbo, Benito Almirante, Pierluigi Viale, Antonio Oliver, Vicente Pintado, Oriol Gasch, Luis Martínez-Martínez, Johann Pitout, Murat Akova, Carmen Peña, Jose Molina Gil-Bermejo, Alicia Hernández, Mario Venditti, Nuria Prim, German Bou, Evelina Tacconelli, Mario Tumbarello, Axel Hamprecht, Helen Giamarellou, Manel Almela, Federico Pérez, Mitchell J Schwaber, Joaquín Bermejo, Warren Lowman, Po-Ren Hsueh, José Ramón Paño-Pardo, Julián Torre-Cisneros, Maria Souli, Robert A Bonomo, Yehuda Carmeli, David L Paterson, Álvaro Pascual, Jesús Rodríguez-Baño
发表日期
2017/10/30
期刊
Clinical Infectious Diseases
卷号
65
期号
10
页码范围
1615-1623
出版商
Oxford University Press
简介
Background
There is little information about the efficacy of active alternative drugs to carbapenems except β-lactam/β-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems.
Methods
A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed.
Results
Overall, 335 patients were included; 249 received …
学术搜索中的文章
ZR Palacios-Baena, B Gutiérrez-Gutiérrez, E Calbo… - Clinical Infectious Diseases, 2017